An adjuvant approach to Cancer therapy:
Innovation through simplification ...
Advantagene: Making the “Standard of Care” for cancer work better
Advantagene executes a capital-efficient and nimble business model. Capital-efficient operations and strategic financing, have allowed Advantagene to remain closely held and thus exercise nimble and product-focused decisions. This approach is further facilitated by Advantagene’s technology and clinical strategy, which are also inherently cost and time efficient.
Advantagene has manufacturing, clinical, and regulatory expertise.
Over the past 20 years members of Advantagene’s team have played key roles in the scientific and regulatory evolution of this biologic product class and its clinical development, including leadership positions at the NIH Recombinant DNA Advisory Committee (RAC) and FDA’s Vaccine and Related Products Advisory Committee (VRPAC) and Biologic Response Modifiers Advisory Committee (BRMAC).
Advantagene’s drugs are designed to work with radiation, chemotherapy and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. The products are based on a technology called Gene Mediated Cytotoxic Immunotherapy (GMCI™), which is a unique and highly effective method of inducing a tumor-specific systemic immune response. The products are stable with regular refrigeration, come as a vialed product and are simple to administer with minimal or no toxicity. The whole process can be carried out in an outpatient setting. GMCI™ is a very attractive approach to add to standard of care because it is specific and non-toxic.
Advantagene’s lead products are in advanced stages of clinical development. ProstAtak™, for prostate cancer, has completed a Phase II study with positive results and received Fast-Track designation from the FDA. GliAtak™, a malignant glioma product, has completed a Phase I dose finding study with highly encouraging results, received funding from the National Institutes of Health for further development and has received Orphan Drug designation from the FDA. A follow-on Phase Ib/randomized Phase II study is in progress. In addition the company has a Phase I study open for its pancreatic cancer product, PancAtak™.
Advantagene also has a full pipeline of clinical products (see Clinical Trials) that target major cancers at the initial removal of primary tumors to prevent local and metastatic recurrence. The company has exclusive worldwide rights to intellectual property related to this novel cancer immunotherapy. A successful outcome with any of these agents will provide a very marketable product and a benefit to thousands of patients and families worldwide.
Advantagene has manufacturing, clinical, and regulatory expertise.
Over the past 20 years members of Advantagene’s team have played key roles in the scientific and regulatory evolution of this biologic product class and its clinical development, including leadership positions at the NIH Recombinant DNA Advisory Committee (RAC) and FDA’s Vaccine and Related Products Advisory Committee (VRPAC) and Biologic Response Modifiers Advisory Committee (BRMAC).
Advantagene’s drugs are designed to work with radiation, chemotherapy and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. The products are based on a technology called Gene Mediated Cytotoxic Immunotherapy (GMCI™), which is a unique and highly effective method of inducing a tumor-specific systemic immune response. The products are stable with regular refrigeration, come as a vialed product and are simple to administer with minimal or no toxicity. The whole process can be carried out in an outpatient setting. GMCI™ is a very attractive approach to add to standard of care because it is specific and non-toxic.
Advantagene’s lead products are in advanced stages of clinical development. ProstAtak™, for prostate cancer, has completed a Phase II study with positive results and received Fast-Track designation from the FDA. GliAtak™, a malignant glioma product, has completed a Phase I dose finding study with highly encouraging results, received funding from the National Institutes of Health for further development and has received Orphan Drug designation from the FDA. A follow-on Phase Ib/randomized Phase II study is in progress. In addition the company has a Phase I study open for its pancreatic cancer product, PancAtak™.
Advantagene also has a full pipeline of clinical products (see Clinical Trials) that target major cancers at the initial removal of primary tumors to prevent local and metastatic recurrence. The company has exclusive worldwide rights to intellectual property related to this novel cancer immunotherapy. A successful outcome with any of these agents will provide a very marketable product and a benefit to thousands of patients and families worldwide.